CLGN · CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. is an Israeli regenerative medicine company leveraging proprietary plant-based recombinant human collagen (rhCollagen) technology for medical aesthetics and 3D bioprinting applications. The company's pipeline includes a photocurable regenerative dermal filler and regenerative 3D-bioprinted breast implants, alongside its commercially available Collink.3D bioink platform. The filing highlights a critical strategic inflection point: in April 2026, AbbVie (Allergan) exercised its right to terminate the development and commercialization agreement originally signed in February 2021. This termination, effective June 2026, necessitates a strategic pivot, prompting management to actively seek new partnerships while implementing a 50% workforce reduction to extend the cash runway into the fourth quarter of 2026.

Financially, the company faces significant challenges. The filing explicitly states there is substantial doubt about its ability to continue as a going concern. As of December 31, 2025, the accumulated deficit stood at approximately $124.8 million, with total equity of only $6.1 million. The February 2026 registered direct offering raised approximately $2 million in gross proceeds at $1.25 per share, a stark contrast to the $3.00 per share price secured in the June 2025 financing. This pricing disparity, combined with the current trading price of $0.29 (as of April 14, 2026), reflects severe valuation pressure and potential dilution for existing shareholders.

This F-1/A filing registers 3,296,000 ordinary shares for resale by selling shareholders, comprising shares issuable upon exercise of Series A, Series B, and Placement Agent warrants. The company will not receive proceeds from these secondary sales, though it could receive up to $4.15 million if all warrants are exercised for cash. The registration follows standard procedural requirements to allow warrant holders to sell underlying shares, but the influx of potential supply onto the market poses a risk to the already depressed stock price. The termination of the AbbVie partnership removes a validated development pathway and milestone payments, increasing execution risk as the company must independently navigate regulatory and commercialization hurdles or secure new collaborators in a competitive landscape.